SCHEMBL10280647

SCHEMBL10280647

Cc1ccc2c(c1C)NC(=O)CC2c1cccc(Cl)c1

nearest known ligand 0.71

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ TP53 P04637 3/20 0.71
▸ LMNA P02545 5/20 0.55
▸ TDP1 Q9NUW8 2/20 0.47
▸ ALDH1A1 P00352 2/20 0.47
▸ MAPK1 P28482 1/20 0.47
▸ KMT2A Q03164 4/20 0.45
▸ GAA P10253 2/20 0.45
▸ KIF11 P52732 1/20 0.44
▸ L3MBTL1 Q9Y468 1/20 0.44
▸ SMN1; SMN2 Q16637 2/20 0.43
▸ HTT P42858 3/20 0.43
▸ MAPT P10636 1/20 0.43
▸ PKM P14618 1/20 0.40
▸ NPSR1 Q6W5P4 1/20 0.40
▸ MEN1 O00255 2/20 0.39
▸ NPC1 O15118 2/20 0.39
▸ RAB9A P51151 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13522432 0.88 LMNA (0.56) TP53LMNATDP1ALDH1A1MAPK1
SCHEMBL10280290 0.81 LMNA (0.70) TP53LMNATDP1ALDH1A1KMT2A
SCHEMBL880487 0.79 LMNA (0.67) TP53LMNATDP1ALDH1A1MAPK1
SCHEMBL880374 0.79 LMNA (0.64) TP53LMNATDP1ALDH1A1MAPK1
SCHEMBL880435 0.79 MAPT (0.68) TP53LMNATDP1ALDH1A1MAPK1
SCHEMBL880235 0.78 LMNA (0.51) TP53LMNATDP1KMT2AGAA
SCHEMBL13522407 0.78 LMNA (0.66) TP53LMNATDP1ALDH1A1KMT2A
SCHEMBL10280721 0.76 LMNA (0.54) TP53LMNATDP1ALDH1A1MAPK1
SCHEMBL880264 0.76 LMNA (0.67) TP53LMNATDP1ALDH1A1KMT2A
SCHEMBL30005837 0.76 LMNA (0.67) TP53LMNATDP1ALDH1A1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130289022-A1 TETRAMERIC ALPHA-SYNUCLEIN AND USE THEREOF BRANDEIS UNIVERSITY (US) 2013-10-31 — — US disclosed
US-8440705-B2 2,3,4,7,8,9-hexahydro-1H-cyclopenta[h]quinolin-2-one or 2,3,4,6,7,8-hexahydro-1H-cyclopenta[g]quinolin-2-one; Alzheimer's disease WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) 2013-05-14 — — US disclosed
EP-2433634-A2 Compounds, compositions and methods of inhibiting a-synuclein toxicity The Whitehead Institute for Biomedical Research (US) 2012-03-28 — — EP disclosed
US-20100004277-A1 COMPOUNDS AND METHODS FOR MODULATING PROTEIN TRAFFICKING FOLDRX PHARMACEUTICALS, INC. (US) 2010-01-07 — — US disclosed
US-20100004277-A1 COMPOUNDS AND METHODS FOR MODULATING PROTEIN TRAFFICKING FOLDRX PHARMACEUTICALS, INC. (US) 2010-01-07 — — US disclosed
US-20080261953-A1 Compounds, Compositions and Methods of Inhibiting Alpha-Synuclein Toxicity WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) 2008-10-23 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080261953-A1 Compounds, Compositions and Methods of Inhibiting Alpha-Synuclein Toxicity SNCA, PARK7, HTT TP53 1529/4885LMNA 525/4885TDP1 556/4885
US-20100004277-A1 COMPOUNDS AND METHODS FOR MODULATING PROTEIN TRAFFICKING GOLT1B, NPC1L1, NPC1 TP53 3445/4885LMNA 3569/4885TDP1 2826/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback